The Life Sciences team advised AMAG Pharmaceuticals (NASDAQ: AMAG) on its definitive agreement under which Covis Group S.à r.l. will acquire AMAG for $13.75 per share in cash, or approximately $498 million on a fully diluted basis and approximately $647 million on an enterprise basis, including debt obligations expected to be assumed or repaid net of cash. The offer represents a premium of approximately 46% to the closing price of AMAG’s common stock on September 30, the last full trading day prior to the announcement.
AMAG is a commercial-stage biopharmaceutical company focused on bringing innovative products to patients with unmet medical needs. The company does this by leveraging its development and commercial expertise to invest in and grow its pharmaceutical products across a range of therapeutic areas. Covis is headquartered in Luxembourg with operations in Zug, Switzerland and is a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses.
The Goodwin team was led by Stuart Cable and Jacqueline Mercier, and included Lillian Kim, Chukwudi Udeogalanya, Will Stanton, Hayden Hutto, Sarah Bock, Morgan Frisoli, Jennifer Bralower, Reid Bagwell, Janet Andolina, Alex Plaum, Andrea Murino, Kirby Lewis, Matt Wheatley, Deborah Birnbach, Adam Slutsky, Jennifer Luz, Jim Barri, Theresa Kavanaugh, Megan Gustafson, Rich Matheny, James Brower, Justin Pierce, Jennifer Fay, Caroline Galiatsos, and Brian Mukherjee, with invaluable assistance from Shaleena Alli-Rampersad.
For more details, read the press release.